8-K: PDS Biotech Announces Positive Clinical Trial Data and First Quarter 2024 Financial Results

PDS Biotechnology reported positive updated data from its Phase 2 VERSATILE-002 clinical trial and its first quarter 2024 financial results, highlighting progress in its cancer immunotherapy programs.

Summary

• PDS Biotechnology announced updated results from the VERSATILE-002 Phase 2 trial, showing a median overall survival of 30 months for patients with recurrent or metastatic head and neck cancer treated with Versamune HPV and KEYTRUDA, compared to published results of 7-18 months for immune checkpoint inhibitors.
• The trial met its primary endpoint of best overall response, with a 34% response rate in patients with a Combined Positive Score (CPS) of 1 and 48% in patients with a CPS of 20, compared to published results of less than 20% and 25% respectively for immune checkpoint inhibitors.
• Progression-free survival was 6.3 months for patients with CPS1 and 14.1 months for patients with CPS20, compared to 2-3 months for immune checkpoint inhibitors.
• The company is planning a two-part registrational trial focusing on a triple combination therapy of Versamune HPV, PDS01ADC, and pembrolizumab.
• PDS Biotech also expanded its intellectual property portfolio with new patents granted in Israel and Australia, extending protection for its Versamune platform through 2038 and 2036 respectively.
• For the first quarter of 2024, the company reported a net loss of approximately $10.6 million, or $0.30 per share, compared to a net loss of $9.7 million, or $0.32 per share, for the same period in 2023.
• Research and development expenses increased to approximately $6.7 million, while general and administrative expenses decreased to approximately $3.4 million.
• The company's cash and cash equivalents totaled approximately $66.6 million as of March 31, 2024.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results and intellectual property expansion, which are strong indicators of future potential. However, the increased net loss and reliance on future financing temper the overall sentiment slightly.

Positives

• The VERSATILE-002 trial demonstrated significantly improved overall survival and response rates compared to existing treatments.
• The combination therapy was well tolerated by patients.
• The company has strengthened its intellectual property position with new patents.
• The company has a strong cash position of $66.6 million.

Negatives

• The company reported a net loss of $10.6 million for the first quarter of 2024, an increase from the $9.7 million loss in the same period of 2023.
• Research and development expenses increased by $0.9 million compared to the same period last year.

Risks

• The company is dependent on additional financing to fund its operations and complete the development and commercialization of its product candidates.
• The company has a limited operating history in its current line of business, making it difficult to evaluate its prospects.
• Clinical trial results may not be indicative of final results.
• The company's ability to continue as a going concern is dependent on future financing.

Future Outlook

The company plans to initiate a pivotal clinical trial in 2024 to advance its lead program in advanced head and neck squamous cell cancers (HNSCC).

Management Comments

• The company believes that proof-of-concept long-term data have shown positive survival results and tumor shrinkage with the combination therapy.
• The company believes that the PDS01ADC and Versamune HPV immunotherapy has shown compelling results with potential to successfully disrupt a tumor's inside defenses, while also generating potent, targeted killer T-cells to attack the tumor from the outside.
• The company believes that data from more than 350 patients, as well as ongoing clinical trials across multiple tumor types and standard treatment regimens, have validated the potential for both platforms and point to potential broad utility.

Industry Context

The announcement highlights the ongoing advancements in cancer immunotherapy, particularly in the treatment of head and neck cancers. The positive results from the VERSATILE-002 trial position PDS Biotech as a potential competitor in the space, offering a novel approach with its Versamune platform.

Comparison to Industry Standards

• The median overall survival of 30 months in the VERSATILE-002 trial significantly exceeds the 7-18 months typically seen with immune checkpoint inhibitors like Keytruda in similar patient populations.
• The best overall response rates of 34% (CPS1) and 48% (CPS20) are also notably higher than the less than 20% and 25% respectively reported for immune checkpoint inhibitors.
• The progression-free survival of 6.3 months (CPS1) and 14.1 months (CPS20) is also significantly better than the 2-3 months typically seen with immune checkpoint inhibitors.
• These results suggest that PDS Biotech's combination therapy may offer a more effective treatment option compared to current standards of care, potentially competing with companies like Merck (Keytruda) and others developing similar immunotherapies.

Management Changes

Stakeholder Impact

• Shareholders may view the positive clinical trial results and intellectual property expansion favorably.
• Employees may be encouraged by the company's progress and future prospects.
• Patients with head and neck cancer may benefit from the potential new treatment options.
• The company's suppliers and partners may see increased business opportunities.

Next Steps

• The company plans to initiate a pivotal clinical trial in 2024 for its lead program in advanced head and neck squamous cell cancers (HNSCC).
• The company will proceed with a two-part registrational trial focused on the triple combination of Versamune HPV, PDS01ADC, and pembrolizumab.

Key Dates

Keywords

immunotherapy, cancer, head and neck cancer, HNSCC, Versamune, KEYTRUDA, pembrolizumab, PDS01ADC, clinical trial, intellectual property, biotechnology